id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-E-6736-0007,FDA,FDA-2017-E-6736,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2019-09-17T04:00:00Z,2019,9,2019-09-17T04:00:00Z,,2019-09-17T13:47:48Z,,0,0,0900006483f86ce2
FDA-2017-E-6736-0006,FDA,FDA-2017-E-6736,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2019-01-28T05:00:00Z,2019,1,2019-01-28T05:00:00Z,,2019-01-28T15:04:33Z,,0,0,0900006483a17510
FDA-2017-E-6736-0005,FDA,FDA-2017-E-6736,"Determination of Regulatory Review Period for Purposes of Patent
Extension; XERMELO",Notice,Determinations,2018-12-28T05:00:00Z,2018,12,2018-12-28T05:00:00Z,2019-02-27T04:59:59Z,2018-12-31T21:26:53Z,2018-28218,0,0,09000064839cbee3
FDA-2017-E-6736-0004,FDA,FDA-2017-E-6736,Letter from the U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2018-10-02T04:00:00Z,2018,10,2018-10-02T04:00:00Z,,2018-10-02T12:51:21Z,,0,0,090000648378a8fc
FDA-2017-E-6736-0003,FDA,FDA-2017-E-6736,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2018-01-12T05:00:00Z,2018,1,2018-01-12T05:00:00Z,,2018-01-12T19:48:39Z,,0,0,0900006482df07a9
FDA-2017-E-6736-0002,FDA,FDA-2017-E-6736,Letter from U.S. Patent and Trademark Office to CDER,Other,Letter(s),2017-12-05T05:00:00Z,2017,12,2017-12-05T05:00:00Z,,2017-12-05T13:22:16Z,,0,0,0900006482cdbbf0
FDA-2017-E-6736-0001,FDA,FDA-2017-E-6736,"Patent Extension Application from Squire Patent Boggs (US) LLP (on behalf of Lexicon Pharmaceuticals, Inc.)",Other,Application,2017-12-05T05:00:00Z,2017,12,2017-12-05T05:00:00Z,,2017-12-05T13:18:04Z,,0,0,0900006482cdbbee